Search Results

Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.

Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® medicines for osteoporosis and cancer-related bone loss respectively.

NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health.

Bio-Thera Solutions (688177:SH) and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab).

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

NEXGEL, Inc. announced a partnership with STADA Arzneimittel AG, a European leader in consumer health, to distribute and commercialize consumer health OTC products in North America in 2024.

Partners STADA and Alvotech announced that the Committee for Medicinal Products for Human Use within the European Medicines Agency has adopted a positive opinion for Uzpruvo, a biosimilar candidate to Stelara®.

Partners STADA and Calliditas Therapeutics AB announced the submission of a request to the European Medicines Agency for the Committee for Medicinal Products for Human Use to convert the conditional marketing authorization for Kinpeygo®, their treatment for primary IgA nephropathy, to standard, or “full”, marketing authorization.